FOLH1 and posterior cortical atrophy: PSMA-PET may be a prognostic tool for recurrent PCa [8,9], and has the potential to be the optimal procedure for image-guided MDT, as was recently proposed in the PEACE V-STORM trial [10] (a phase 2 randomized study in which nodal pelvic oligorecurrent PCa patients based on PET imaging were randomized to receive MDT+ 6 months of ADT or whole pelvic radiotherapy + MDT + 6 months of ADT with metastasis-free survival as the primary outcome).